Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...

The primary goal of depot somatostatin-analogue (SSA) therapy for acromegaly is to reduce disease activity by suppressing growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion. A test ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

This was a 48-week, international, open-label, prospective trial of octreotide LAR. Eligible participants were aged 18–80 years with a biochemical diagnosis of acromegaly. Patients who had already ...